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Abstract
Geographic or ethnic differences in the occurrence of disease
often provide insights into causes of disease and possible
opportunities for disease prevention. Persons in China appear to
have a consistently lower prevalence of rheumatoid arthritis and
fibromyalgia than persons in the United States and Europe; reasons
for these prevalence differences might include genetic differences,
differences in environmental exposures or a combination of both.
With increasing obesity, gout is becoming endemic in China.
Finally, symptomatic knee osteoarthritis is extremely common in
China and constitutes a major public health problem there.
In the present issue of Arthritis Research and Therapy Zeng
and colleagues comprehensively review studies evaluating
the prevalence of rheumatic disease in China [1]. Their report
suggests variations in the prevalence of symptomatic
osteoarthritis throughout China, consistent prevalences for
ankylosing spondylitis and rheumatoid arthritis, an absence of
fibromyalgia, and a temporal increase in the prevalence of
gout. What should we make of all of these estimates and why
are they important to us outside China?
Estimates of the prevalence of rheumatic disease provide
information about the burden of disease and suggest a need
for provision of health services. For knee osteoarthritis, where
the prevalence in China is high and knee replacements are
not widely available [2], there may be a need for additional
provision of health services.
Comparing the prevalence of disease from one region with
another often provides insights into disease etiology. For
example, coronary heart disease rates increased as Japanese
migrated from Japan to Hawaii to mainland United States,
suggesting that diet and environment were major causes of
coronary heart disease. For systemic lupus, which was not
evaluated by Zeng and colleagues, a prevalence gradient
exists with low prevalence of lupus occurring in Africans,
moderate rates along the slave trade route among African
descendents living in the Caribbean, and high rates in the
United States [3]. Using data from the article by Zeng and
colleagues, we can make inferences about differences in
disease prevalence that might provide clues regarding
rheumatic disease etiology.
Zeng and colleagues reviewed diverse studies, many of them
using the Community Oriented Program for the Control of
Rheumatic Diseases (COPCORD) protocol. The COPCORD
has been a joint initiative by the World Health Organization
and the International League of Associations for
Rheumatology whose goal was to provide information about
the epidemiology of rheumatic disease in developing
countries. The COPCORD methods require comprehensive
population-based sampling with a rigorous protocol
translated into the language of interest, and then, for persons
with rheumatic complaints, there is follow-up testing and
often evaluation by a rheumatologist to determine how many
persons have identifiable diseases.
Estimates of rheumatic disease derived from the COPCORD
and other studies have varied and, despite the impressive
standardization of this protocol, variations in prevalence rates
are probably still due, in part, to differences in how the
studies are carried out from site to site. Also, for rheumatoid
arthritis, many of these studies only detected a few cases in a
community, so the estimate of prevalence is accompanied by
wide confidence bounds, and there was substantial variation
in prevalence from community to community. Another
variation source is that crude prevalence estimates are
usually presented, whereas age-standardized prevalence
would often be more informative, especially since rheumatic
diseases vary in prevalence by age. An additional source of
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variation is that some of the studies may not sample large
numbers of older people who tend to have the highest
prevalence of many rheumatic diseases, including rheumatoid
arthritis. Finally, participation rates may differ in each study.
While most COPCORD studies have reported participation
rates exceeding 80% [4,5], some studies in Asia have not been
so successful [6], and the failure to include persons with
rheumatic diseases might seriously lower prevalence estimates.
Notwithstanding these limitations, the estimates by Zeng and
colleagues suggest rheumatic disease prevalence rates in
China that are different from those in the western hemisphere
or Europe. Among these different rates is a prevalence of
rheumatoid arthritis in China of roughly 0.2–0.3% of the
population versus a prevalence of 0.8% in the western world
[7]. The genes predisposing to rheumatoid arthritis may differ
among Han Chinese versus mixed populations from the
western world. Viral infectious triggers also could
predominate in the West or could infect persons at an age
when their response to infections was most likely to cause
rheumatoid arthritis in genetically susceptible individuals,
whereas similar individuals might be infected at a less
susceptible age in China. Certainly, studies of Asian migrants
to the western world might help determine whether Asians
retain a lower prevalence of rheumatoid arthritis, or whether
their rate after migration rises to that of the surrounding
population, suggesting that environmental risk factors are the
main cause of disease.
Zeng and colleagues report a prevalence of ankylosing
spondylitis that is similar in China to reported estimates from
the western world. In general, the prevalence of HLA-B27 in
the community determines its prevalence of spondylo-
arthropathies. In the Han ethnic population HLA-B27 is
present in between 4% and 6% of persons, a figure lower
than that in Caucasians in the United States. This would be
consistent with a lower prevalence of ankylosing spondylitis
in China than the United States, rather than a comparable
prevalence. Further documentation of this absence of a
prevalence gradient should be confirmed with studies using
broader definitions of disease (for example, undifferentiated
spondyloarthropathy).
Gout has become more prevalent in China, a phenomenon
also seen the United States in recent years. Causes include
increasing rates of obesity and of aging in both populations,
both risk factors strongly associated with the occurrence of
gout. The dramatic increase in gout in China probably reflects
the rapid westernization and urbanization of the society.
Finally, the absence of fibromyalgia in China could be
explained by genetic differences in the processing of afferent
nociceptors throughout the body or by the absence of central
sensitization, a phenomenon thought to be closely tied to the
development of fibromyalgia. Clearly some causes of fibro-
myalgia are sociocultural, and it is possible that the different
cultural environment in China might affect the acceptability of
reporting chronic generalized pain. Investigation of the
fibromyalgia prevalence in migrant Chinese communities
might provide insights into which factors account for the
exceedingly low prevalence of fibromyalgia in China. In
addition, given the import of genetic variations in explaining
racial and ethnic differences in chronic pain [8,9], an
assessment of the prevalence of these genetic abnormalities
in persons of Han ancestry might be of interest.
In summary, Zeng and colleagues have comprehensively
summarized the prevalence of different rheumatic diseases in
China. Their results present a mosaic of rheumatic disease
prevalence, which differs from the rheumatic disease
distributions in the western world. For those of us from the
West interested in better understanding the etiology of
rheumatic disease, the prevalence gradients that can be
inferred from these data regarding rheumatoid arthritis and
fibromyalgia, both of which may be considerably less
common in China than in the western world, might provide
important insights into what causes these diseases.
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